HMPSF: AI 评分 41/100 — AI 分析 (4月 2026)

The Hempshire Group, Inc. is involved in sourcing, manufacturing, branding, and processing pharmaceutical-grade hemp and CBD products. Founded in 2019, the company operates in the specialty and generic drug manufacturing industry.

Key Facts: AI Score: 41/100 Sector: Healthcare

公司概况

概要：

The Hempshire Group, Inc., established in 2019, focuses on the pharmaceutical-grade hemp and CBD product sector. Operating with a small team, the company engages in sourcing, manufacturing, and branding, distinguishing itself in the competitive specialty and generic drug manufacturing industry through its focus on hemp-derived products.

HMPSF是做什么的？

The Hempshire Group, Inc., founded in 2019 and based in Palm Springs, California, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. The company is involved in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Hempshire's focus is on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. The company's operations encompass the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. With a small team of 8 employees, Hempshire navigates the complexities of the pharmaceutical industry, targeting consumers seeking hemp and CBD-based health and wellness solutions. The company's strategic focus on pharmaceutical-grade products underscores a commitment to quality and regulatory compliance, differentiating it from other players in the hemp and CBD market.

HMPSF的投资论点是什么？

The Hempshire Group, Inc. presents a high-risk, high-reward investment profile. The company's negative P/E ratio of -1.97 and a profit margin of -7300.9% indicate significant challenges in achieving profitability. However, its gross margin of 28.8% suggests potential in its core operations if costs can be managed effectively. A beta of 0.12 indicates low volatility compared to the market. Growth catalysts include potential expansion of its product line and increased market penetration in the growing CBD sector. The company's small size and limited resources pose risks, but successful execution of its business plan could lead to substantial returns. Investors should carefully consider the company's financial position and competitive landscape before investing.

HMPSF在哪个行业运营？

The Hempshire Group, Inc. operates in the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for alternative medicines and wellness products. The CBD market, in particular, is expanding rapidly, but faces regulatory uncertainty and intense competition. Hempshire's focus on pharmaceutical-grade hemp and CBD products positions it within a niche segment that emphasizes quality and compliance. The company competes with both established pharmaceutical companies and smaller, specialized CBD manufacturers. Success in this market requires effective branding, distribution, and adherence to evolving regulatory standards.

Drug Manufacturers - Specialty & Generic

Healthcare

HMPSF有哪些增长机遇？

Expansion of Product Line: Hempshire can expand its product line to include a wider range of CBD-infused products, such as topicals, edibles, and beverages. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. By diversifying its offerings, Hempshire can attract a broader customer base and increase revenue streams. Successful product development and marketing will be crucial for capturing market share.
Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies or retailers could provide Hempshire with access to wider distribution networks and increased brand visibility. Collaborations can also facilitate research and development efforts, leading to innovative product formulations. The timeline for establishing such partnerships is dependent on negotiation and due diligence processes, but could yield significant benefits within the next 1-2 years.
International Expansion: Exploring opportunities to expand into international markets, particularly in Europe and Asia, where the demand for CBD products is growing, represents a significant growth driver. Navigating regulatory requirements and establishing distribution channels in new markets will be essential for successful international expansion. This initiative could take 2-3 years to fully implement, but offers long-term growth potential.
Focus on Research and Development: Investing in research and development to create novel CBD formulations and delivery methods can provide Hempshire with a competitive advantage. Developing proprietary technologies and intellectual property can also attract investment and partnership opportunities. The timeline for R&D initiatives can vary depending on the complexity of the projects, but could yield significant results within 3-5 years.
Direct-to-Consumer Sales: Establishing a strong online presence and direct-to-consumer sales channel can improve margins and provide greater control over the customer experience. Investing in e-commerce infrastructure and digital marketing can drive online sales and build brand loyalty. This initiative can be implemented relatively quickly, with noticeable results within the next 6-12 months.

Market capitalization of $0.02 billion, indicating a micro-cap company.
Negative P/E ratio of -1.97, reflecting current losses.
Profit margin of -7300.9%, highlighting significant operational inefficiencies.
Gross margin of 28.8%, suggesting potential for profitability with improved cost management.
Beta of 0.12, indicating lower volatility compared to the overall market.

HMPSF提供哪些产品和服务？

Sources pharmaceutical-grade hemp.
Manufactures CBD products.
Brands and markets its products.
Processes hemp for various applications.
Focuses on the healthcare sector.
Operates in the specialty and generic drug manufacturing industry.

HMPSF如何赚钱？

Sourcing high-quality hemp.
Manufacturing CBD products.
Branding and marketing for direct sales and distribution.
Processing hemp for pharmaceutical applications.

Consumers seeking hemp-based wellness products.
Patients looking for alternative treatments.
Retailers and distributors of health and wellness products.

Focus on pharmaceutical-grade quality.
Specialization in hemp and CBD products.
Established branding and marketing strategies.
Proprietary processing techniques.

什么因素可能推动HMPSF股价上涨？

Upcoming: Potential regulatory changes in the CBD market could create new opportunities for Hempshire.
Ongoing: Expansion of product line to include new CBD-infused products.
Ongoing: Strategic partnerships with established pharmaceutical companies or retailers.

HMPSF的主要风险是什么？

Potential: Intense competition in the CBD market could erode market share.
Potential: Regulatory uncertainty and changing laws could negatively impact operations.
Ongoing: Fluctuations in hemp prices could affect profitability.
Ongoing: Limited financial resources may hinder growth initiatives.
Potential: Negative P/E ratio and profit margin indicate financial instability.

HMPSF的核心优势是什么？

Focus on pharmaceutical-grade hemp and CBD products.
Established brand in a growing market.
Proprietary processing techniques.
Experienced management team.

HMPSF的劣势是什么？

Small size and limited resources.
Negative profitability and high losses.
Reliance on a niche market.
Limited distribution network.

HMPSF有哪些机遇？

Expansion of product line.
Strategic partnerships with larger companies.
International market expansion.
Increased research and development.

HMPSF面临哪些威胁？

Intense competition in the CBD market.
Regulatory uncertainty and changing laws.
Fluctuations in hemp prices.
Economic downturn affecting consumer spending.

HMPSF的竞争对手是谁？

American Premium Water Corporation — Focuses on infused beverages. — (AMHV)
Australis Capital Inc — Cannabis investment company. — (ATHJF)
48North Cannabis Corp — Canadian cannabis company. — (BFFTF)
The Gram Co Inc — Cannabis cultivation and retail. — (GRAMF)
Medical Cannabis Corp — Focuses on medical cannabis research. — (MGCLF)

Key Metrics

MoonshotScore: 41/100

Company Profile

CEO: Shawn Balaghi
Headquarters: Palm Springs, US
Employees: 8
Founded: 2022

AI Insight

AI analysis pending for HMPSF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does The Hempshire Group, Inc. do?

The Hempshire Group, Inc. engages in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Operating in the healthcare sector, the company focuses on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. Hempshire's business model encompasses the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. The company targets consumers seeking hemp and CBD-based health and wellness solutions.

What do analysts say about HMPSF stock?

As of 2026-03-17, there is no readily available analyst consensus on HMPSF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, indicate financial challenges. Growth considerations include the potential for expansion in the CBD market and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with investing in micro-cap OTC stocks before making any investment decisions.

What are the main risks for HMPSF?

The main risks for The Hempshire Group, Inc. include intense competition in the CBD market, regulatory uncertainty and changing laws, fluctuations in hemp prices, and limited financial resources. The company's negative P/E ratio and profit margin also indicate financial instability. As an OTC-listed company, HMPSF faces additional risks related to liquidity, disclosure requirements, and regulatory oversight. Investors should carefully consider these risks before investing in HMPSF stock.